Analysts have recently upgraded their ratings for Arcus Biosciences (NYSE:RCUS), indicating a positive shift in market sentiment for the biopharmaceutical company. On Saturday, Wall Street Zen elevated its rating from “sell” to “hold,” reflecting a more optimistic view of the company’s prospects.
Another significant endorsement came from Citigroup, which reaffirmed a “buy” rating on December 12, while UBS Group followed suit with a similar rating on December 15. Additionally, Truist Financial set a price target of $30.00 for Arcus shares, and Wells Fargo & Company established a price target of $23.00 with an “equal weight” rating on February 12. Morgan Stanley maintained an “equal weight” rating but adjusted its price objective to $20.00, down from $23.00, on January 8.
Research indicates that out of eleven analysts covering Arcus Biosciences, seven have assigned a “buy” rating, three have a “hold” rating, and one has issued a “sell” rating. According to data from MarketBeat.com, the company holds a consensus rating of “Moderate Buy” with an average price target of $29.33.
Recent Quarterly Performance
Arcus Biosciences shared its quarterly earnings on February 25, revealing that it achieved earnings per share of ($0.89). This figure surpassed analysts’ consensus estimates of ($1.11) by $0.22. Despite this positive surprise, the company reported a negative return on equity of 65.77% and a net margin of 142.91%. During the quarter, Arcus generated $33.00 million in revenue, significantly exceeding the consensus estimate of $24.94 million. However, this represented an 8.3% decline compared to the same quarter last year.
Looking ahead, analysts anticipate that Arcus Biosciences may report earnings of ($3.15) per share for the current fiscal year.
Insider Activity and Institutional Investment
In addition to analyst ratings, insider trading activity has also drawn attention. Chief Accounting Officer Alexander Azoy sold 4,343 shares on December 18 for an average price of $22.25, resulting in a total transaction value of $96,631.75. Following this sale, Azoy retained 18,531 shares valued at approximately $412,314.75, marking an 18.99% reduction in his position.
Similarly, General Counsel Carolyn C. Tang sold 6,810 shares on December 17 at an average price of $22.16, totaling $150,909.60. Following the transaction, Tang held 124,734 shares worth around $2,764,105.44, reflecting a decline of 5.18% in her ownership.
In the last quarter, insiders sold a total of 263,987 shares, valued at $6,025,620. Currently, insiders hold approximately 9.60% of the company’s stock.
Institutional investors have also been active in adjusting their holdings in Arcus Biosciences. During the fourth quarter, T. Rowe Price Investment Management Inc. acquired a new stake valued at approximately $39,000. Invesco Ltd. boosted its holdings by 41.7%, now owning 414,365 shares worth $9,874,000. The State of Tennessee Department of Treasury increased its position by 34.2%, now holding 34,855 shares valued at $831,000.
Wellington Management Group LLP expanded its stake by an impressive 309.4%, gaining 5,184,509 shares worth $123,547,000 after purchasing an additional 3,918,220 shares.
Arcus Biosciences continues to navigate a competitive landscape in the biopharmaceutical sector. The company is focused on developing innovative cancer immunotherapies, utilizing its research platform to modulate tumor microenvironments and immune checkpoints. With a variety of clinical programs underway, including etrumadenant and domvanalimab, Arcus aims to enhance antitumor immune responses through targeted therapies.
As investor interest and analyst ratings shift, Arcus Biosciences remains a company to watch in the biopharmaceutical arena.
